MiniMed Group Inc 2025年度报告

Commission File Number 001-43183 MiniMed Group, Inc.(Exact name of registrant as specified in its charter) Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes໨No໪Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes໪No໨ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes໪No໨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See thedefinitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section 1(a) of the Exchange Act.໨Indicate by check mark whether the registrant has¿led a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting¿rm that prepared or issued its audit report.໨If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error topreviously issued financial statements.໨Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executiveofficers during the relevant recovery period pursuant to §240.10D-1(b).໨Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes໨No໪As of October 24, 2025, the last business day of the registrant’s most recently completed second fiscal quarter, there was no public market for the registrant’s common equity. The registrant’scommon stock began trading on The Nasdaq Stock Market LLC on March 6, 2026.As of June 19, 2026, there were 280,842,845 shares of the registrant’s common stock, par value $0.01, issued and outstanding. Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement for its 2026 Annual General Meeting to be filed with the Securities Exchange Commission not later than 120 days after the end of the fiscalyear covered by this Form 10-K are incorporated by reference into Part III hereof. TABLE OF CONTENTS CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains, and management may make, certain “forward-looking statements” within the meaning of the Private Securities LitigationReform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. Words such as “anticipate,” “believe,”“could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “will,” and similar wordsor expressions are used to identify these forward-looking statements. These statements include, among other things, MiniMed Group, Inc.’s (“MiniMed’s”or the “Company’s”) statements about: •our ability to drive long-term stockholder value;•development and future launches of products and continued or future acceptance of products, therapies, and services in our segments;•expected timing for completion of research studies relating to our products;•integration of new technologies, including AI and data analytics, into our products, therapies, and services;•market positioning and performance of our products, including stabilization of certain product markets;•divestitures and the potential benefits thereof;•the costs and benefits of integrating previous acquisitions;•anticipated timing for U.S. FDA and non-U.S. regulatory approval or clearance of new products;•increased presence in new markets, including markets outside the United States;•changes in the market and our market share;•our ability to meet growing demand for our existing products; acquisitions and investment initiatives, including the timing of regulatory approvalsas well as integration of acquired companies into our operations;•the resolution of tax matters;•our approach towards cost containment;•our expectatio